載入...
Comprehensive in vitro pro‐arrhythmic assays demonstrate that omecamtiv mecarbil has low pro‐arrhythmic risk
Omecamtiv mecarbil (OM) is a myosin activator (myotrope), developed as a potential therapeutic agent for heart failure with reduced ejection fraction. To characterize the potential pro‐arrhythmic risk of this novel sarcomere activator, we evaluated OM in a series of International Conference on Harmo...
Na minha lista:
| 發表在: | Clin Transl Sci |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley and Sons Inc.
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8301593/ https://ncbi.nlm.nih.gov/pubmed/33955165 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.13039 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|